Massimiliano Bonifacio, Gianni Binotto, Elena Maino, Elisabetta Calistri, Luciana Marin, Luigi Scaffidi, Luca Frison, Federico De Marchi, Mauro Krampera, Giampiero Semenzato, Renato Fanin, Achille Ambrosetti, Mario Tiribelli. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. haematol [Internet]. 2015Aug.3 [cited 2024Nov.25];100(8):e299-e301. Available from: https://haematologica.org/article/view/7473